iBio(US:IBIO) Benzingaยท2025-10-23 08:07Core Insights - iBio Inc. (NASDAQ:IBIO) has seen a significant increase in stock price, trading up 11.51% to $1.55 in pre-market sessions, following a 25.23% rise to $1.39 in the previous day's regular session [1][2] Company Announcements - iBio announced that its executives will present data on its obesity treatment candidate, IBIO-610, at two industry conferences in November [2] - Dr. Cory Schwartz will present on November 4 in Atlanta, focusing on a first-in-class Activin E antagonist antibody for obesity treatment, including data from nonhuman primate studies [3] - CEO Martin Brenner will present on November 12 in Lisbon, discussing the fat-selective weight loss effects of the anti-Activin E antibody in diet-induced obese mice [3] Stock Performance - Year-to-date, iBio's stock is down 43.27%, but it has gained 82.89% over the past six months [4] - The stock has a 52-week range of $0.56 to $6.89, with a market capitalization of $28.15 million and an average daily trading volume of 2.64 million shares [4] - Current analysis indicates that IBIO is experiencing long-term consolidation in its stock performance [4]